Xiaobao Yang

4.0k total citations
53 papers, 1.9k citations indexed

About

Xiaobao Yang is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Xiaobao Yang has authored 53 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Molecular Biology, 28 papers in Oncology and 13 papers in Hematology. Recurrent topics in Xiaobao Yang's work include Protein Degradation and Inhibitors (22 papers), Ubiquitin and proteasome pathways (16 papers) and Multiple Myeloma Research and Treatments (13 papers). Xiaobao Yang is often cited by papers focused on Protein Degradation and Inhibitors (22 papers), Ubiquitin and proteasome pathways (16 papers) and Multiple Myeloma Research and Treatments (13 papers). Xiaobao Yang collaborates with scholars based in China, United States and Australia. Xiaobao Yang's co-authors include Biao Jiang, Jian Jin, Ning Sun, Xing Qiu, Yue Xiong, Chaowei Ren, Xiaoran Han, Renhong Sun, Jing Liu and Chengwei Zhang and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Xiaobao Yang

49 papers receiving 1.8k citations

Peers

Xiaobao Yang

ONCOL

HEMAT

CMN

PRM

Ester Fernández‐Salas United States

Julianne L. Holleran United States

Weisheng Xu United States

Katrina J. Falkenberg Australia

Søren Østergaard Denmark

Michael J. Orsini United States

Dirk Spitzer United States

Kotaro Sakamoto Japan

Avgi Mamalaki Greece

Bryan Knuckley United States

Ester Fernández‐Salas United States

Xiaobao Yang

1.6k ×1.1

517 ×0.8

ONCOL

261 ×0.7

HEMAT

294 ×1.9

CMN

194 ×1.3

PRM

Citations per year, relative to Xiaobao Yang Xiaobao Yang (= 1×) peers Ester Fernández‐Salas

Countries citing papers authored by Xiaobao Yang

Since Specialization

Citations

This map shows the geographic impact of Xiaobao Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaobao Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaobao Yang more than expected).

Fields of papers citing papers by Xiaobao Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaobao Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaobao Yang. The network helps show where Xiaobao Yang may publish in the future.

Co-authorship network of co-authors of Xiaobao Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaobao Yang. A scholar is included among the top collaborators of Xiaobao Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaobao Yang. Xiaobao Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yang, Xiaobao, et al.. (2025). Survival outcomes in small intestine tumors: The role of duodenum, jejunum, and ileum. International Journal of Cancer. 157(3). 445–454.

Hu, Ye, Haofei Li, Junlin Chen, et al.. (2025). Artificial intelligence-assisted wearable porous eutectogel with high-performance NH3 enrichment and visual sensing enables non-invasive monitoring of chronic kidney disease. Chemical Engineering Journal. 507. 160678–160678. 8 indexed citations

Wu, Wenyong, Renhong Sun, Dingyan Wang, et al.. (2024). Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia. Cancer Research. 85(1). 101–117. 4 indexed citations

Yang, Xiaobao, Danping Liu, Yujie Zhu, et al.. (2024). Identifying the Spatial Architecture That Restricts the Proximity of CD8+ T Cells to Tumor Cells in Pancreatic Ductal Adenocarcinoma. Cancers. 16(7). 1434–1434. 4 indexed citations

Yang, Xiaobao, et al.. (2023). Diagnostic Value of Inflammation-Related Indicators in Distinguishing Early Colon Cancer and Adenomatous Polyps. Cancer Control. 30. 2915598793–2915598793. 9 indexed citations

Zhang, Yanchun, Renhong Sun, Xiaotong Zhu, et al.. (2023). Development of the nonreceptor tyrosine kinase FER-targeting PROTACs as a potential strategy for antagonizing ovarian cancer cell motility and invasiveness. Journal of Biological Chemistry. 299(6). 104825–104825. 9 indexed citations

Yang, Xiaobao, Na Zeng, Zhigang Bai, et al.. (2023). BRCA genes as candidates for colorectal cancer genetic testing panel: systematic review and meta-analysis. BMC Cancer. 23(1). 807–807. 7 indexed citations

Yang, Xiaobao, et al.. (2023). Sarcobesity, but not visceral fat, is an independent risk factor for complications after radical resection of colorectal cancer. Frontiers in Nutrition. 10. 1126127–1126127. 10 indexed citations

Wang, Junyun, Mingyue Zhu, Zhigang Bai, et al.. (2022). Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. Cancer Immunology Immunotherapy. 71(11). 2597–2608. 34 indexed citations

10.

Li, Fenglei, Qiaoyu Hu, Renhong Sun, et al.. (2022). DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs. Nature Communications. 13(1). 7133–7133. 88 indexed citations

11.

Sun, Renhong, Haixia Liu, Chaowei Ren, et al.. (2022). Design, synthesis and biological evaluation of novel quinazolinone derivatives as CRBN E3 ligase modulators. European Journal of Medicinal Chemistry. 247. 115016–115016. 3 indexed citations

12.

Yang, Yong, et al.. (2022). Combined Consideration of Tumor-Associated Immune Cell Density and Immune Checkpoint Expression in the Peritumoral Microenvironment for Prognostic Stratification of Non-Small-Cell Lung Cancer Patients. Frontiers in Immunology. 13. 811007–811007. 8 indexed citations

13.

Lin, Jinrong, Xiaobao Yang, Shaohua Liu, et al.. (2021). Long non‐coding RNA MFAT1 promotes skeletal muscle fibrosis by modulating the miR‐135a‐5p‐Tgfbr2/Smad4 axis as a ceRNA. Journal of Cellular and Molecular Medicine. 25(9). 4420–4433. 15 indexed citations

14.

Wu, Xuewei, Xiaobao Yang, Yan Xiong, et al.. (2021). Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders. Nature Cancer. 2(4). 429–443. 47 indexed citations

15.

Pang, Kai, Jun Li, Xiaobao Yang, et al.. (2021). Prophylactic subcutaneous drainage reduces post-operative incisional infections in colorectal surgeries: a meta-analysis of randomized controlled trials. International Journal of Colorectal Disease. 36(8). 1633–1642. 3 indexed citations

16.

Ren, Chaowei, Ning Sun, Ying Kong, et al.. (2021). Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib. European Journal of Medicinal Chemistry. 217. 113335–113335. 38 indexed citations

17.

Bai, Zhigang, Jun Zhang, Hongpeng Jiang, et al.. (2021). Apatinib plus S-1 for previously treated, advanced gastric or gastro-oesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. Journal of Gastrointestinal Oncology. 12(5). 2035–2044. 4 indexed citations

18.

Sun, Ning, Chaowei Ren, Ying Kong, et al.. (2020). Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. European Journal of Medicinal Chemistry. 193. 112190–112190. 66 indexed citations

19.

Zhang, Bing, Jun Li, Xiaolin Yang, et al.. (2019). Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target. Cell. 176(3). 636–648.e13. 183 indexed citations

20.

Ma, Anqi, Ηλίας Στρατικόπουλος, Kwang‐Su Park, et al.. (2019). Discovery of a first-in-class EZH2 selective degrader. Nature Chemical Biology. 16(2). 214–222. 167 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact